BioAffinity Other Current Assets from 2010 to 2024

BIAFW Stock  USD 0.75  0.15  25.00%   
BioAffinity Technologies Other Current Assets yearly trend continues to be fairly stable with very little volatility. Other Current Assets will likely drop to about 220.1 K in 2024. Other Current Assets is assets expected to be converted into cash, sold, or consumed either in one year or in the operating cycle, which are not included under standard current asset categories. View All Fundamentals
 
Other Current Assets  
First Reported
2010-12-31
Previous Quarter
321 K
Current Value
220.1 K
Quarterly Volatility
144.8 K
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check BioAffinity Technologies financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among BioAffinity Technologies' main balance sheet or income statement drivers, such as Depreciation And Amortization of 262.1 K, Interest Expense of 35.3 K or Gross Profit of 831.2 K, as well as many indicators such as Price To Sales Ratio of 4.82, Dividend Yield of 0.0 or PTB Ratio of 2.78. BioAffinity financial statements analysis is a perfect complement when working with BioAffinity Technologies Valuation or Volatility modules.
  
Check out the analysis of BioAffinity Technologies Correlation against competitors.

Latest BioAffinity Technologies' Other Current Assets Growth Pattern

Below is the plot of the Other Current Assets of bioAffinity Technologies Warrant over the last few years. It is assets expected to be converted into cash, sold, or consumed either in one year or in the operating cycle, which are not included under standard current asset categories. BioAffinity Technologies' Other Current Assets historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in BioAffinity Technologies' overall financial position and show how it may be relating to other accounts over time.
Other Current Assets10 Years Trend
Slightly volatile
   Other Current Assets   
       Timeline  

BioAffinity Other Current Assets Regression Statistics

Arithmetic Mean103,869
Geometric Mean60,510
Coefficient Of Variation139.42
Mean Deviation101,522
Median37,493
Standard Deviation144,811
Sample Variance21B
Range497.9K
R-Value0.62
Mean Square Error14B
R-Squared0.38
Significance0.01
Slope19,983
Total Sum of Squares293.6B

BioAffinity Other Current Assets History

2024220.1 K
2023321 K
2022531.9 K
202176.1 K
202034 K

About BioAffinity Technologies Financial Statements

BioAffinity Technologies investors use historical fundamental indicators, such as BioAffinity Technologies' Other Current Assets, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in BioAffinity Technologies. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Other Current Assets321 K220.1 K

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for BioAffinity Stock Analysis

When running BioAffinity Technologies' price analysis, check to measure BioAffinity Technologies' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy BioAffinity Technologies is operating at the current time. Most of BioAffinity Technologies' value examination focuses on studying past and present price action to predict the probability of BioAffinity Technologies' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move BioAffinity Technologies' price. Additionally, you may evaluate how the addition of BioAffinity Technologies to your portfolios can decrease your overall portfolio volatility.